PCM
FBRX icon

Prelude Capital Management’s Forte Biosciences FBRX Stock Holding History

Prelude Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-80
Closed -$327K – 1802
2019
Q1 		$327K Buy
+80
New +$309K 0.02% 583
2018
Q4 		– Hold
0
– – – 1712

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Prelude Capital Management's FBRX Position: Q2 2019 in Review

Prelude Capital Management sold out of Forte Biosciences (FBRX) in Q2 2019, closing a stake of 80 shares — an estimated $327K sold.

Prelude Capital Management first reported a position in FBRX in Q1 2019 and held it in 1 quarter. The position peaked at $327K in Q1 2019. 74 funds tracked by Wall St. Rank hold FBRX as of Q2 2019.

  • Prelude Capital Management reported no remaining Forte Biosciences position as of Q2 2019 after selling out during the quarter.
  • Prelude Capital Management sold 80 Forte Biosciences shares in Q2 2019, an estimated $327K.
  • Prelude Capital Management first reported a position in Forte Biosciences in Q1 2019 and held it in 1 quarter.
  • Prelude Capital Management's Forte Biosciences position peaked at $327K in Q1 2019.
  • 74 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2019.

Based on Prelude Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.